Amgen To Build State-Of-The-Art Manufacturing Facility In Singapore

     Amgen To Build State-Of-The-Art Manufacturing Facility In Singapore

PR Newswire

THOUSAND OAKS, Calif., Jan. 16, 2013

THOUSAND OAKS, Calif., Jan. 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today
announced plans to build a new manufacturing facility in the Tuas Biomedical
Park area of Singapore. Over the next several years, Amgen anticipates
investing approximately $200 million to build an innovative new facility,
which will initially focus on expanding Amgen's manufacturing capability for
monoclonal antibodies. The facility will be capable of manufacturing both
clinical and commercial products.

"Amgen is pleased to be planning for a new world-class facility in Singapore
as part of our global expansion strategy. Singapore is an ideal location to
further our manufacturing efforts based on its rich talent pool and friendly
business environment," said Madhu Balachandran, executive vice president of
Operations at Amgen.

Construction is expected to begin in the next few months, and the site will be
staffed with both new recruits and experienced staff. Amgen is currently
partnering with local universities to recruit for a number of positions in
Manufacturing and Quality.

About Amgen
As one of the industry's original innovators, Amgen has extensive knowledge
and first-hand expertise in clinical and commercial manufacturing of
biotechnology-based medicines as well as a track record of safely and reliably
delivering medicines to patients who need them.

Amgen discovers, develops, manufactures and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe and effective
medicines from lab, to manufacturing plant, to patient. Amgen therapeutics
have changed the practice of medicine, helping millions of people around the
world in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and our vital medicines, visit Follow us on

Forward-Looking Statements
This news release contains forward-looking statements that involve significant
risks and uncertainties, including those discussed below and others that can
be found in our Form 10-K for the year ended Dec. 31, 2011, and in our
periodic reports on Form 10-Q and Form 8-K. Amgen is providing this
information as of the date of this news release and does not undertake any
obligation to update any forward-looking statements contained in this document
as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ
materially from those we project.The Company's results may be affected by our
ability to successfully market both new and existing products domestically and
internationally, clinical and regulatory developments (domestic or foreign)
involving current and future products, sales growth of recently launched
products, competition from other products (domestic or foreign) and
difficulties or delays in manufacturing our products. In addition, sales of
our products are affected by reimbursement policies imposed by third-party
payers, including governments, private insurance plans and managed care
providers and may be affected by regulatory, clinical and guideline
developments and domestic and international trends toward managed care and
health care cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement.Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and foreign
government regulatory authorities.We, or others, could identify safety, side
effects or manufacturing problems with our products after they are on the
market.Our business may be impacted by government investigations, litigation
and product liability claims. Further, while we routinely obtain patents for
our products and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete with other
companies with respect to some of our marketed products as well as for the
discovery and development of new products.Discovery or identification of new
product candidates cannot be guaranteed and movement from concept to product
is uncertain; consequently, there can be no guarantee that any particular
product candidate will be successful and become a commercial product.Further,
some raw materials, medical devices and component parts for our products are
supplied by sole third-party suppliers. Our business performance could affect
or limit the ability of our Board of Directors to declare a dividend or our
ability to pay a dividend or repurchase our common stock.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)



Press spacebar to pause and continue. Press esc to stop.